(WOMAN, 68 Y/O, AREDS 3)
A female subject, aged 68, diagnosed with Age-Related Macular Degeneration (AMD) classified under the Age-Related Eye Disease Study (AREDS) Category 3, was incorporated into the multicentric, randomised controlled investigation termed LightWave I.
At baseline, the subject’s best-corrected visual acuity was quantified at 50 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart.
The subject underwent a regimen of photobiomodulation (PBM) employing Light Modulation® Low-Level Light Therapy (LM® LLLT) via the eye-light® system. The treatment protocol entailed bi-weekly sessions spanning a four-week duration.
Subsequent to a one-month interlude post the culmination of the therapy, a reevaluation of the subject’s best-corrected visual acuity manifested an enhancement to 55 ETDRS letters. Additionally, a complete resolution of certain soft drusen was observed.
Figures 1, 2, and 3, which are retinal images of the identical eye, depict a marked decrement in the volume of drusen within the macular region, corroborating the therapeutic efficacy of the intervention.
Source
LightWave I Case Reports © 2023 Espansione Group, All Rights Reserved
About Espansione Group
Espansione Group is an established player in the medtech industry. Espansione Group strives to deliver the highest standard in the industry. Every day, the company invests heavily in researching and developing the Espansione Ecosystem to achieve its ambition: establishing new paradigms in ophthalmology and beyond, driven by its desire to provide its partners and their patients with the best, certified medical technologies, Light Modulation® Low-level Light Therapy (LM® LLLT) and Optimal Power Energy® Intense Pulsed Light (OPE® IPL). Present in over 50 countries, Espansione Group’s aims to continue its strong growth in years to come, relentlessly focusing its efforts on research, development, and customer excellence. For more information, visit www.espansionegroup.it